TLDR:
- Alamar Biosciences secures $128 million in series C funding to support the launch of its Argo HT protein analyzer and NULISAseq inflammation panel.
- The investment was led by Sands Capital, with additional unnamed investors participating in the round.
Alamar Biosciences, a protein sequencing company, has raised $128 million in venture capital funding to facilitate the commercial rollout of its research hardware. The series C funding round, which includes an initial closing of $100 million, was led by Sands Capital. The remaining $28 million is expected to be secured within the next month. The company’s Argo HT automated protein analyzer, launched at the beginning of this year, offers multiplexing support for various biomarker profiling tasks and can process up to 288 samples per batched run.
Alamar also introduced the NULISAseq inflammation panel to analyze the body’s defensive responses in autoimmune disorders, neurodegenerative diseases, cardiovascular disease, and cancer. The company’s CEO, Yuling Luo, expressed excitement about the platform’s ability to meet the growing need for high sensitivity, multiplexed protein detection. The successful placements of the Argo HT system in six U.S. sites, along with 10 purchase orders from early access program participants, demonstrate the market demand for their innovative solutions.
In addition to its proteomic liquid biopsy platform NULISA, Alamar collaborated with Frazier Life Sciences to establish Attovia Therapeutics, a joint venture focused on developing biotherapeutics for immune-mediated diseases and cancer. This collaboration, launched in June 2023 with $60 million in series A financing, aims to advance therapies targeting a wide range of immune system proteins.
Overall, Alamar Biosciences’ latest funding round highlights the increasing interest in advanced protein sequencing technologies and their potential to revolutionize the field of proteomics research and biomarker analysis.
